03:54 PM Abstract No. 108 Is conventional transarterial chemoembolization for neuroendocrine tumor liver metastasis really the best management option or is it reflective of lead-time bias?
A recent review of transarterial chemoembolization with conventional chemotherapy (cTACE), drug-eluting beads, or yttrium-90 radioembolization (Y90) for liver metastasis of neuroendocrine tumors (NELM) suggests cTACE has the longest overall and progress-free survival. However, it fails to control the duration of disease prior to presenting for liver directed therapy (LDT). Our study aims to identify potential lead time (L-T) bias that may affect therapy choice and subsequent outcomes.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: B. Bones, S. Burner, S. Mohammad, V. Shivaji, M. Miller, R. Durrani, K. Dickey, T. Downing, B. Kouri Tags: Scientific Session 11: Chemoembolization Liver Source Type: research
More News: Brain | Chemotherapy | Liver | Neurology | Neuroscience | Radiology | Study | Urology & Nephrology